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Introduction: Cancer-related pain has a severe negative impact on quality of life. Combination 
analgesic therapy with oxycodone and pregabalin is effective for treating neuropathic cancer 
pain. We investigated the efficacy and tolerability of a dose-escalation combination therapy 
with prolonged-release oxycodone/naloxone (OXN-PR) and pregabalin in patients with non-
small-cell lung cancer and severe neuropathic pain.
Methods: This was a 4-week, open-label, observational study. Patients were treated with 
OXN-PR and pregabalin. Average pain intensity ([API] measured on a 0–10 numerical rating 
scale) and neuropathic pain (Douleur Neuropathique 4) were assessed at study entry and at 
follow-up visits. The primary endpoint was response to treatment, defined as a reduction of API 
at T28 30% from baseline. Secondary endpoints included other efficacy measures, as well as 
patient satisfaction and quality of life (Brief Pain Inventory Short Form), Hospital Anxiety and 
Depression Scale, and Symptom Distress Scale; bowel function was also assessed.
Results: A total of 56 patients were enrolled. API at baseline was 8.0±0.9, and decreased 
after 4 weeks by 48% (4.2±1.9; P0.0001 vs baseline); 46 (82.1%) patients responded to 
treatment. Significant improvements were also reported in number/severity of breakthrough 
cancer pain episodes (P=0.001), Brief Pain Inventory Short Form (P=0.0002), Symptom 
Distress Scale (P0.0001), Hospital Anxiety and Depression Scale depression (P=0.0006) 
and anxiety (P0.0001) subscales, and bowel function (P=0.0003). At study end, 37 (66.0%) 
patients were satisfied/very satisfied with the new analgesic treatment. Combination therapy 
had a good safety profile.
Conclusion: OXN-PR and pregabalin were safe and highly effective in a real-world setting 
of severe neuropathic cancer pain, with a high rate of satisfaction, without interference on 
bowel function.
Keywords: oxycodone/naloxone, opioids, pregabalin, neuropathic cancer pain, non-small-cell 
lung cancer, breakthrough cancer pain
Introduction
Severe chronic pain affects most patients with advanced cancer; current guidelines 
recommend strong around-the-clock opioids as first-line therapy to achieve adequate 
control of moderate-to-severe chronic pain.1,2
Treatment of cancer-related neuropathic pain includes antidepressants, anticon-
vulsant agents, topical lidocaine, and oral opioids. Although alleviated by opioids, 
chronic neuropathic pain seems less responsive than nociceptive pain to opioids, and 
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so these drugs are considered second- or third-line analgesics 
in this setting.3–5 Given the multifactorial pathogenesis of 
neuropathic pain, current guidelines recommend combination 
pharmacotherapy in the management of this heterogeneous 
and complex condition.1,2 The combination of gabapentin 
and alpha-lipoic acid has been shown to be effective in neu-
ropathic pain.6 The combination of controlled-release oxy-
codone and pregabalin was found as an effective long-term 
option for non-cancer pain treatment, and this combination 
significantly reduced oxycodone dosages.7
Nevertheless, many cancer patients still do not receive 
adequate pain control.8,9 The poor gastrointestinal (GI) toler-
ability of opioids is one of the causes of their limited compli-
ance and inadequate analgesia.10 Opioids exert their analgesic 
effect primarily interacting with the μ-receptors in the central 
nervous system; their activation of μ-receptors in the GI tract 
also causes opioid-induced bowel dysfunction (OIBD), with 
constipation, abdominal cramps, nausea and vomiting: all 
these symptoms often interfere with the analgesic efficacy 
of opioids, causing substantial distress, impairing treatment 
adherence and quality of life (QoL).10,11
The oral prolonged-release oxycodone/naloxone 
(OXN-PR) combination in a fixed 1:2 ratio has been shown 
to be associated with superior GI tolerability.12,13 The 
powerful μ-opioid receptor antagonist naloxone is added 
to counteract OIBD by blocking the oxycodone action at 
opioid receptors locally in the gut; the extensive first-pass 
hepatic metabolism of naloxone and its low (3%) systemic 
bioavailability after oral administration ensure the lack of 
antagonistic effects on oxycodone central analgesic action. 
The OXN-PR formulation has been found to be analgesi-
cally effective, while improving OIBD and decreasing the 
use of rescue medications and laxatives.12,14,15 However, 
a few prospective studies on OXN-PR in cancer patients are 
available;14,16 moreover, the value of OXN-PR in combina-
tion with pregabalin in the treatment of severe neuropathic 
cancer pain has never been tested.
Our study was aimed at evaluating the efficacy, tolerabil-
ity, and effect on GI function of OXN-PR in association with 
pregabalin in patients with lung cancer and severe malignant 
pain in a real-world clinical setting.
Methods
This 28-day, single-center, prospective observational study 
was conducted at the Palliative Care and Cancer Pain Service, 
San Camillo-Forlanini Hospital, Rome, Italy. The study was 
approved by the Ethics Committee of San Camillo-Forlanini 
Hospital, and all patients gave written informed consent for 
the collection and analysis of their anonymous demographic 
and clinical data.
Design of the study
From January 2013 to May 2014, males and females 18 years 
of age with non-small-cell lung cancer (NSCLC) referred 
to our specialist Pain Unit were screened and considered 
for this study if they had a history of debilitating pain that 
required continued around-the-clock opioid therapy. Patients 
previously untreated with pregabalin and with uncontrolled 
pain despite other opioid treatment, or with side effects con-
traindicating further dosage increase and requiring switch to 
another opioid, were also considered.
The inclusion criteria for our study were: 1) presence 
of severe pain at baseline, defined as average pain intensity 
(API) score 7 on a 0–10 numerical rating scale (NRS; where 
0 indicates no pain and 10 the worst imaginable pain) that 
occurred within the 24 hours preceding the screening visit and 
requiring WHO step III analgesics (strong opioids) and 2) a 
clear neuropathic component of pain, caused either from pri-
mary or metastatic compression of nervous structures, or from 
invasive procedures or cancer treatments including surgery, 
radiation, and chemotherapy. The “definite” neuropathic 
component was established according to pain description 
(eg, shooting, burning, tingling sensation with numbness, 
painful cold, pins and needles, localization to specific der-
matomes, or nerve distributions), physical evaluation, and 
a 4 score at the Douleur Neuropathique 4 (DN4) Inventory, 
a questionnaire used for the diagnosis of neuropathic pain 
based on pain descriptors and bedside sensory examination.17,18 
The inclusion criteria also included Eastern Cooperative 
Oncology Group Performance Status score 3 and an esti-
mated survival expectancy 2 months.
Patients were excluded from the study if changes of che-
motherapy occurred, or patients underwent radiotherapy on 
the lesion that caused the neuropathic pain in 3 weeks before 
enrollment or throughout the study; diagnosis of neuropathy 
prior to the diagnosis of cancer, as well as neuropathy consid-
ered unrelated to cancer; cognitive impairment or dementia not 
allowing correct pain assessment; symptomatic cerebral metas-
tases or known psychiatric disease; severe respiratory disease 
with hypoxemia and/or hypercapnia; moderate or severe liver 
(total bilirubin 1.5 mg/dL) and or renal insufficiency (glom-
erular filtration rate 30 mL/min); paralytic ileus; history of 
alcohol and drug abuse; inability to take oral medication; and 
known hypersensitivity to the study medications.
Regular visits were scheduled at baseline (prior to the 
start of the treatment, T0), after 14 days (T14) and 28 days 
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(T28), and the end of the observation. Additional visits were 
possible at all times according to individual patient needs 
(eg, if patients had inadequate pain control, difficult analge-
sics titration, and/or adverse events [AEs]).
study drugs
At the T0 visit, in the absence of contraindications, all patients 
were prescribed oral OXN-PR (Targin® tablets, Mundipharma 
Pharmaceuticals, Milan, Italy) and pregabalin (Lyrica® tab-
lets, Pfizer Limited, Sandwich, UK), and were instructed to 
interrupt other analgesics and/or anticonvulsants. Ongoing 
acetaminophen and/or adjunctive therapy with steroids were 
confirmed with no further dose increase for the observation 
period. Other treatments for any other underlying medical 
condition were continued unchanged, including laxatives.
The starting OXN-PR dose was determined individu-
ally according to the age, health status, previous analgesic 
therapy, and patient’s needs: in patients naïve to opioids, 
OXN-PR was started at 5/2.5 or 10/5 mg, twice daily (bid), 
and the first tablet was administered at 8 pm. In previously 
opioid-treated patients, starting OXN-PR doses were chosen 
equivalent to morphine dosage, according to traditional 
conversion tables. Patients not achieving acceptable pain 
control were instructed to increase their OXN-PR doses in 
the following week, with daily increments of 5/2.5–10/5 mg, 
until patient reported satisfied with pain relief, or  emergence 
of poor tolerability, and/or a maximum daily dose of 
60/30 mg (patients naïve to opioids) or 80/40 mg of OXN-PR 
(patients opioid-pretreated). After 7 days, the study investiga-
tor or a palliative care-certified nurse made telephone calls 
to the patients to ensure that the patients were taking proper 
doses of OXN-PR. At the subsequent T14 visit, the OXN-
PR-titrated dose was confirmed or changed by the visiting 
pain clinician according to the patients’ needs, side effects, 
or other inconveniences related to OXN-PR, and the daily 
OXN-PR dose for the following 2-week period was adjusted 
accordingly.
The starting pregabalin dose was 25 mg bid, or 75 mg 
bid if patients were pretreated with gabapentin. If API was 
still 4 after the first 7-day treatment, and no side effects 
were reported, patients uptitrated their pregabalin daily dose 
every 3 days by 50 mg increments, up to a maximum dose 
of 300 mg daily until the achievement of appropriate pain 
relief and in the absence of side effects.19
At the T0 visit, oral immediate-release morphine sulfate 
10 mg was also prescribed as rescue medication, up to a maxi-
mum of three doses per day; patients were also instructed 
to contact our center in advance of their scheduled control 
in case of rescue morphine daily dosing more than twice. 
Sublingual or transmucosal fentanyl as rapid onset opioid was 
prescribed for the management of episodes of breakthrough 
cancer pain (BTCP), ie, the transitory exacerbation of pain, 
with a rapid onset and severe in intensity, with a specific 
unpredictable or predictable trigger or occurring spontane-
ously, despite an adequately controlled background pain.2
assessment
At the T0 visit, demographic and clinical data were recorded, 
as well as details on pain, ongoing treatments, and constipa-
tion. At every visit, API related to the preceding 24 hours 
was rated on an 11-point NRS. Patients were also required to 
record the daily number of BTCP, the intensity of this later 
on an 11-point NRS, as well as the use of rescue analgesics 
for its treatment.
T0 and T28 evaluation also included the following:
1. Interference of pain in the patient’s life, evaluated by 
a validated Brief Pain Inventory Short Form (BPI-SF) 
national version;20 BPI-SF 7-item composite pain 
interference includes general activity, walking ability, 
normal work, mood, enjoyment of life, sleep, and rela-
tions with other people, with a 11-point scale for each 
item, ranging from 0= no impairment to 10= most severe 
impairment.
2. Symptoms of anxiety and depression, assessed using a 
validated Hospital Anxiety and Depression Scale (HADS) 
questionnaire for outpatients: it detect states of anxiety 
and depression on two 7-item scales, one for anxiety and 
one for depression, each ranging from 0= absent or normal 
to 3= most severe impairment (sum score 1–7= normal, 
8–10= mildly affected, 11–21= moderately to severely 
affected).21,22
3. Health-related QoL, assessed using the four items on 
emotional functioning of the European Organization 
for Research and Treatment of Cancer Quality of Life 
Questionnaire-Core 30 (EORTC QLQ-C30).23 EORTC 
QLQ-C30 is a cancer-specific questionnaire composed 
of both multi-item scales and single-item measures. 
Patients reported their symptom extent based on the 
descriptors: 1 (not at all), 2 (a little), 3 (quite a bit), and 
4 (very much), thus higher scores indicating a worse level 
of functioning.24
4. Distress due to cancer-related symptoms assessed with 
the Symptom Distress Scale (SDS):25,26 patients scaled the 
intensity and frequency of nausea, anorexia, insomnia, 
bowel pattern, respiration, coughing, fatigue, concentra-
tion, appearance, and mood from 1 to 5, with items rated 3 
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or higher indicating serious distress (a summed score 25 
indicates moderate distress, scores 33 indicate severe 
distress).27
5. Bowel function, in particular symptoms of constipa-
tion, which was considered as clinically significant if 
patients reported less than three complete spontaneous 
bowel movements, with difficulty passing stools despite 
laxatives and/or appropriate dietary modifications. Bowel 
function in the last 7 days was also evaluated by the Bowel 
Function Index (BFI): scores range from 0 (free from 
symptoms) to 100 (most severe symptoms); in patients 
with chronic pain, a BFI value of 29 is set as upper normal 
limit.28
At the T28 visit, patients’ satisfaction with the effi-
cacy and tolerability of the new analgesic treatment was 
rated as very satisfied, satisfied, moderately satisfied, or 
dissatisfied.
safety
At each time point, any new AE that occurred or worsened 
in intensity and/or frequency after the intake of OXN-PR 
and pregabalin was recorded; the potential correlation 
between the AE and the new antalgic treatment was judged 
by the pain therapist. This safety evaluation considered only 
AEs of severe intensity (ie, those persistent despite treat-
ment and requiring discontinuation of the treatment) and/ 
or moderate AEs (ie, those requiring treatment and/or not 
permitting a dose escalation of the treatment, or requiring 
its down-tapering).
statistical analysis
As in other studies assessing analgesic efficacy in cancer 
patients, the primary endpoint of the trial was the proportion 
of patients who achieved a substantial reduction in their pain 
intensity after the new analgesic combination: “Responders” 
were those patients who achieved at T28 a reduction of 
API 30% from baseline.29–31
Secondary endpoints were: mean percentage change in 
API from baseline; the percentage of patients achieving an 
API 5, as well as the percentage reporting satisfaction with 
pain relief; changes in the number and intensity of BTCP 
episodes from baseline; changes in neuropathic pain from 
baseline (DN4 evaluation); and interference of pain in the 
patient’s life (BPI), distress (SDS), anxiety and depression 
(HADS), QoL (EORTC QLQ-C30 evaluation), and bowel 
function (BFI).
According to the given definition, based on a Fleming 
design with 80% power and 5% type 1 error, the study design 
required 39 patients to test the null hypothesis that the true 
confirmed response rate was at most 50%, versus the alterna-
tive hypothesis that it was 70%. Considering the short dura-
tion planned for this observation, to allow for dropouts and 
incomplete data (~25%), at least 49 patients were required. 
Missing data were treated with the “last observation carried 
forward” method.
Data are reported as mean ± standard deviation or median 
and range. Changes over time in categorical variables were 
compared using the Cochran’s Q test, and differences 
between pairs of continuous variables were evaluated by 
Student’s t-test or Wilcoxon test. Continuous variables over 
time were assessed by analysis of variance or Kruskal–Wallis 
analysis. Normality distribution of continuous variables was 
assessed by the Shapiro–Wilk test. A P-value 0.05 was 
considered statistically significant (STATISTICA software, 
version 8.0, StatSoft® Inc., Tulsa, OK, USA).
Results
From January 2013 to May 2014, 60 patients with advanced 
NSCLC and severe pain despite analgesic treatment were 
screened: two patients were not included (terminal illness; 
cognitive limitation), two others were excluded (logistic 
impediments to completing the 4-week observation; no 
informed consent). The remaining 56 patients (93.3% of 
the screened population) were included in the final analysis 
(mean age 64±10, 77% males). Patient flow throughout the 
study is shown in Figure 1. Their demographic and baseline 
clinical characteristics are shown in Table 1. All the patients 
Figure1 Patient disposition and response rate after oxycodone/naloxone and 
pregabalin.
Note: response, 30% pain intensity reduction between the first visit and the 
last visit.
Abbreviation: nsclc, non-small-cell lung cancer.
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were at tumor, node, metastasis classification (TNM, seventh 
edition) stage IV; mean Karnofsky Performance Scale Index 
was 66±10. In more than two-thirds of the patients, bone 
metastases were present. Chemotherapy was the main cancer 
treatment in 38/56 (67.9%) of the patients, and 30/56 (53.6%) 
received also radiation therapy.
Before enrollment, 45 patients (80.4%) were taking 
nonsteroidal anti-inflammatory drugs, and 36 (64.2%) were 
already on opioids (WHO step III drugs in 50% of patients). 
At baseline, all the patients were taking some adjuvant 
therapy; the majority of the patients were taking alpha-lipoic 
acid, two-thirds were treated with steroids, one-third with 
bisphosphonates, and one-fifth were on anticonvulsants 
(gabapentin in all cases).
According to the reported API value at baseline (median 8, 
range 7–10), the enrolled population was suffering from very 
severe pain. At enrollment, pain duration was 30 days in 
29 (51.8%) patients.
At enrollment, the majority of the patients reported BTCP 
episodes (n=51, 91.1%; median, three episodes daily); this 
was of severe intensity (mean NRS, 8.3±2.7). All the patients 
completed the 28-day study observation.
The mean OXN-PR starting dose was 22.1±8.9 mg 
daily (range 10–60 mg). Subsequently, OXN-PR daily dose 
increased to 36.3+15.7 mg at the T28 visit (P0.0001).
Mean pregabalin starting dose was 70.5±39.6 mg daily 
(range 25–150); at the T28 visit, all the patients were still on 
pregabalin, with a mean daily dose slightly increased versus 
baseline (115.0±69.6 mg, range 25–300 mg; P0.0001).
analgesic response
A substantial decrease in reported pain intensity was 
documented with the OXN-PR and pregabalin combination 
(API at T28=4.2±1.9, P0.0001 vs baseline); a signifi-
cant reduction in pain severity was already reported after 
14 days (Figure 2). Mean pain intensity decrease at T28 was 
47.6%±24.3%, and the “waterfall” graph in Figure 3 shows 
the individual changes of pain intensity from baseline to 
T28. At T28, there were 46 (82.1%) responders (ie, those 
with a reduction in daily pain intensity 30% of the corre-
sponding baseline value). Among the remaining ten (17.9%) 
patients with unsatisfactory analgesic response at T28 visit, 
six patients (10.7%) were still complaining of severe pain 
(API 7). On the contrary, 16 patients (28.5%) reported a 
complete or near-complete analgesic benefit (API 0–3) at T28 
(Figure 4). Likewise, the DN4 score was markedly reduced 
at T28 visit (4.5+1.8 vs 6.75+0.86, P0.001).
At the end of the observation, fewer patients still reported 
episodes of BTCP (n=39, 69.6%; P0.005 vs baseline). The 
number of daily episodes also decreased at T28 (2.1±2.3; 
median 2, range 2–12; P=0.001), also of reduced severity 
(NRS 5.7±3.9, P0.001 vs baseline).
Other efficacy results
At study end, all secondary efficacy measures showed sub-
stantial improvement. Daily need of additional acetamino-
phen decreased from 86.8% to 40.4% at T28 (P0.001). 
Pain-related functional impairment also declined (BPI-SF 
composite pain interference score: from 6.9±1.6 to 5.5±1.8; 
P=0.0002). All individual domain scores except quality of 
Table 1 Demographic and clinical characteristics of patients at 
baseline
age, years (range) 64±10 (37–83)
Male sex, n (%) 43 (76.8)
Presence of bone metastases, n (%) 40 (71.2)
Karnofsky performance status, n (%)
50–59 5 (8.9)
60–79 43 (76.8)
80–90 8 (14.3)
Pain, nrs 8.0±0.9
Pain duration, days 47±36
Previous analgesic treatment, n (%)
step i WhO drugs 45 (80.4)
step ii WhO opioids 18 (32.1)
step iii WhO opioids 18 (32.1)
adjuvant pain medications, n (%)
steroids 39 (69.6)
anticonvulsants 13 (23.2)
antidepressants 3 (5.4)
Bisphosphonates 16 (29.1)
alpha-lipoic acid 46 (82.1)
Patients reporting BTcP, n (%) 51 (91.1)
number of daily BTcP episodes 3.2±3.0
Patients reporting constipation, n (%) 20 (35.7)
Bowel Function index 44.6±15.3
Note: Values are mean (± standard deviation).
Abbreviations: nrs, numerical rating scale; BTcP, breakthrough cancer pain; 
WhO, World health Organization.
???????????? ???????? ?????? ??????? ???????
? ?
?
???
????
??
Figure 2 aPi score (11-point nrs) throughout the observation.
Note: *P0.001 versus result at previous time point.
Abbreviations: aPi, average pain intensity; nrs, numerical rating scale.
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sleep decreased from baseline to T28, suggesting less inter-
ference of pain in daily life (Table 2).
In agreement with the favorable BPI-SF finding, health-
related QoL substantially improved at T28 (P0.001, 
Table 2); conversely, distress due to cancer-related symptoms 
????
???
???
???
???
???
???
???
???
???
??
?
??
?
?? ??
??
??
??
??
?
???????? ?????? ??????? ???????
??????? ??????????????
Figure 4 Proportions and numbers of patients with severe (nrs 7–10), moderate 
(nrs 4–6), or mild (nrs 1–3) average pain intensity, or no pain at all (nrs 0) during 
the 28-day observation with OXn-Pr and pregabalin.
Note: six patients still complained of severe pain (nrs 6) after 28 days.
Abbreviations: nrs, numeric rating scale; OXn-Pr, prolonged-release oxycodone/
naloxone.
Table 2 changes in selected data during the 28-day observation
Baseline Day 28 visit P-value
haDs
symptoms of anxiety 8.7±4.0 6.7±2.7 0.0001
symptoms of depression 7.3±3.8 6.1±3.3 0.0006
eOrTc QlQ-c30 items
Tense 3.7±2.1 3.1±2.3 0.008
Worried 4.8±1.7 3.8±1.8 0.002
irritable 3.7±2.8 2.9±2.5 0.01
Depressed 3.9±1.7 3.0±2.2 0.005
symptom Distress scale 35.8±7.7 28.1±7.9 0.0001
Note: Values are mean ± standard deviation.
Abbreviations: haDs, hospital anxiety and Depression scale; eOrTc QlQ-c30, 
european Organization for research and Treatment of cancer Quality of life 
Questionnaire-core 30.
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Figure 3 Waterfall image of individual percentage changes from baseline in pain intensity score (numeric rating scale) among the 56 patients who completed the 
observation.
Notes: Mean pain intensity decrease at study end was 47.6%±24.3% (median -50%, range +14%, -100%). green bars indicate responders.
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decreased substantially over the observation (Table 2): both 
physical and emotional dimensions of SDS scales were 
significantly reduced (P0.0001).
After the new analgesic treatment, a substantial improve-
ment in anxiety and depression symptoms was also recorded, 
as reflected by the significant decrease of HADS subscales 
scores (P0.05 for both) (Table 2).
Tolerability and safety
Although at baseline only one-third (35.7%) of the patients 
reported constipation (Table 1), almost all (83.3%,) showed 
abnormal BFI values (ie, 29); indeed, the median baseline 
BFI value recorded at T0 (48) indicates that half of the patients 
suffered moderate-to severe bowel dysfunction at baseline. 
After OXN-PR and pregabalin, of relevance, none reported 
subjective worsening of their constipation symptoms, or 
constipation of new occurrence. The number of patients still 
complaining of constipation at the end of the study nearly 
reduced to half (n=13, 23.2%; P0.01 in Cochran’s Q test). 
In fact, a significant reduction in the BFI value was found 
after the administration of OXN-PR and pregabalin, thus 
indicating an improvement in bowel function (mean value 
at T28, 28.9±21.7, P0.001 vs baseline).
At the end of the study, 37 (66.0%) patients rated the new 
analgesic treatment positively; 14 (25.0%) and 23 (41.0%) 
said they were either very satisfied or satisfied, respectively. 
Only four patients (7.1%) rated themselves as dissatisfied 
after the administration of the OXN-PR and pregabalin 
combination.
Overall, the OXN-PR and pregabalin combination 
therapy was well tolerated in the 28-day observation. Side 
effects were documented in 26 patients. The most common 
AEs are summarized in Table 3. No severe AEs leading to 
premature discontinuation were recorded. Most AEs were 
mild, without new or unexpected safety signals. The most 
frequent treatment-related AEs were somnolence, confusion, 
asthenia, loss of appetite, and nausea.
Discussion
In cancer patients, pain is often associated with exacerba-
tion of other symptoms, and affects mood, job performance, 
personal relationships, and the overall QoL.32 In the last 
two decades, despite the improvements in quality of phar-
macologic treatment, one-third of cancer patients are still 
not receiving adequate pain management.9 The integration 
of early palliative intervention with anticancer treatment 
can reduce anxiety and depression, improving the QoL and 
prolonging survival.33 According to a recent statement of the 
American Society of Clinical Oncology, “combined standard 
oncology care and palliative care should be considered early 
in the course of illness for any patient with metastatic cancer 
and/or high symptom burden”.34
Pain may be the first sign of lung cancer, and its preva-
lence in patients with lung cancer is one of the highest 
(85%) among different cancer types.8 Extremely few 
data, however, are available on pain management in patients 
with lung cancer; in a small trial conducted in patients with 
NSCLC, subjects randomly assigned to an oral pain treat-
ment protocol encompassing recommendations from existing 
cancer pain guidelines performed significantly better than 
patients managed according to physician preference.35
A neuropathic pain component of pain is present in 30% 
to 50% of patients with lung cancer.36–38 Chemotherapy or 
radiotherapy, combined with general comorbidities and 
impaired functional status, makes neuropathic pain difficult 
to correct, and often adjuvants are added to target specific 
pathways of neuropathic pain.39 Oxycodone plus pregabalin 
has been found to be effective in controlling neuropathic pain 
both in non-cancer and cancer patients.7,40 However, response 
to opioids is often inadequate, requiring higher dosages;19 
and side effects of opioids are common: OIBD, in particular 
constipation, is common and persists, causing considerable 
distress and reduced QoL.11,41
The oral fixed-dose OXN-PR combination has been 
shown to provide analgesic efficacy while improving OIBD 
in cancer patients.14–16,42 A small, open-label study showed 
relevant improvement in pain and bowel function after 
OXN-PR.16 In a randomized controlled trial comparing 
efficacy and safety of oxycodone PR and OXN-PR in opioid-
pretreated patients with controlled pain and constipation at 
baseline, the switch to OXN was associated with a similar 
Table 3 Major side effects reported during the treatment
Adverse eventa Patients, n (%)
any 26 (46.4)
somnolence 18 (32.1)
confusion 8 (14.3)
nausea 5 (8.9)
Vomiting 1 (1.8)
Dry mouth 3 (5.3)
abdominal cramps 1 (1.8)
stomach pain 1 (1.8)
Dysuria 1 (1.8)
anorexia 4 (7.1)
asthenia 9 (16.1)
Notes: aadverse events of moderate severity (ie, those events requiring dose 
tapering or not permitting dose escalation when required). no patient experienced a 
severe side effect leading to premature discontinuation of the analgesic combination. 
numbers do not add up, since several patients reported more than one side effect.
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analgesic effect compared to oxycodone PR, however, with a 
clinically relevant improvement in bowel function.14 A retro-
spective study in 206 patients with uncontrolled pain showed 
OXN to be highly effective and well tolerated in both opioid-
naïve and -pretreated patients, as well as in younger and 
older patients, without adverse effects on bowel function;42 
patients previously treated with OXY were not included in 
that study. Kang et al reported pain exacerbation and opioid 
withdrawal symptoms in a patient with gastric cancer and 
portal vein thrombosis after receiving OXN-PR; hepatic and 
renal function data were not described in the case report.43 
In a recent study comparing OXN-PR and oxycodone-PR in 
cancer patients naïve to strong opioids, the analgesic efficacy 
was found to be comparable, with an overall incidence of 
drug-related AEs remarkably lower after OXN-PR: nausea 
and vomiting were significantly less frequent, with greater 
improvement in QoL following OXN-PR.15
Different from the aforementioned studies, our study is 
the first prospective clinical trial to evaluate the efficacy and 
safety of OXN-PR and pregabalin in cancer patients with neu-
ropathic pain. The target population had severe pain despite 
other non-opioid and opioid analgesic treatment. The major-
ity of patients (82%) achieved the primary endpoint after 
4 weeks of OXN-PR and pregabalin treatment. Pain relief 
was achieved even in patients previously treated with WHO 
step III opioids; the severity of neuropathic pain also declined 
after 28 days, as indicated by the significantly reduced DN4 
values. All secondary efficacy measures improved substan-
tially, with less interference of pain in the patient’s life, less 
distress due to cancer-related symptoms, and improved QoL. 
The reduced bowel discomfort likely improved the adherence 
to the new treatment, contributing to the observed superior 
analgesic effects of the new treatment in comparison with 
previous painkillers. More recently, in a large randomized 
trial, OXN-PR was associated with a significantly better anal-
gesic efficacy, lower risk of OIBD, and superior tolerability 
compared with oxycodone or morphine.44 Of note, ultra-low 
dosages of naloxone could enhance, rather than attenuate, 
the analgesic effects of oxycodone within the central ner-
vous system.45,46 The improved QoL and GI tolerability of 
OXN-PR explain its lower cost-utility estimates compared 
with oxycodone.47
In the present study, the OXN-PR and pregabalin 
combination was well tolerated, and there were no serious 
drug-related AEs. Of note, central nervous system side 
effects, and in particular dizziness and drowsiness, were 
limited. The observed improvement in QoL and patient’s 
satisfaction is in agreement with previous results, showing 
that attenuation of neuropathic pain after opioids improves 
mood and sleep.48,49
This study had several limitations, including the open-label 
observational design, short treatment duration, small sample 
size, and lack of a control group. However, the results of the 
present study provide a solid basis for the design of a larger 
investigation to further assess the efficacy and tolerability of 
the OXN-PR and pregabalin combination for the management 
of severe neuropathic pain in patients with lung cancer.
Conclusion
The opioid agonist–antagonist OXN-PR combination in 
conjunction with pregabalin effectively controlled severe 
neuropathic pain in patients with lung cancer. This drug 
combination did not worsen the bowel function, and also 
resulted in a significant improvement in QoL and patient’s 
satisfaction. Thus, it could represent a valuable option in daily 
clinical practice for the management of severe neuropathic 
cancer pain.
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